COMP <GO>
ANGO vs SGHT // REVENUE GROWTH (YOY)
AngioDynamics Inc. (NASDAQ) VS. Sight Sciences Inc. (NASDAQ) • 15-METRIC TALLY: ANGO 6
— SGHT 4
▲ REVENUE GROWTH (YOY) LEADER: ANGO
LAST: $12.35 (+1.81%) • MKT CAP: $519.4M
revenue-growth
9.50%
LAST: $9.57 (+3.57%) • MKT CAP: $527.2M
revenue-growth
-3.10%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ANGO VS. SGHT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ANGO | SGHT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 54.60% | 86.20% | -31.60 | SGHT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -23.40% | -35.00% | +11.60 | ANGO | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.10% | -5.67% | +5.77 | ANGO | /fcf-yield <GO> |
| Operating Margin | -12.50% | -48.00% | +35.50 | ANGO | /operating-margins <GO> |
| Net Profit Margin | -11.50% | -49.70% | +38.20 | ANGO | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 9.50% | -3.10% | +12.60 | ANGO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.12 | 2.16 | -0.04 | SGHT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 5/9 | +1.00 | ANGO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 39.4 | 59.3 | -19.89 | SGHT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $519.4M | $527.2M | -$7.8M | SGHT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ANGO REV | SGHT REV | ANGO GROSS % | SGHT GROSS % | ANGO FCF | SGHT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $320.2M | $77.4M | 54.6% | 86.2% | $508.0K | -$29.9M |
| FY 2024 | $292.5M | $79.9M | 53.9% | 85.5% | -$14.6M | -$22.7M |
| FY 2023 | $303.9M | $81.1M | — | — | -$28.2M | -$47.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ANGO // BETA —
SGHT // BETA —